News

Merck Gets FDA Approval for Tumor Treatment Welireg
Merck has received approval from the Food and Drug Administration for Welireg, its oral inhibitor for patients with certain rare types of neuroendocrine tumors. The company said Wednesday the ...
MedPage Today5h
FDA OKs New Drug for Lung Cancer With c-Met Overexpression
The FDA granted accelerated approval to telisotuzumab vedotin (Emrelis) for the treatment of adults with previously treated, ...
FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases
FDA grants accelerated approval to AbbVie's Emrelis for c-Met overexpressing NSCLC; siRNA partnership with ADARx includes ...
US FDA approves AbbVie's drug for a type of lung cancer
The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received ...
CURE7h
FDA Approves Emrelis in Previously Treated, Advanced NSCLC
The U.S. FDA has approved treatment with Emrelis for adult patients with previously treated, advanced NSCLC with high c-Met ...
Merck wins FDA label expansion for Welireg in neuroendocrine tumors
Merck (MRK) stock in focus as the FDA approves its anticancer agent Welireg for two rare neuroendocrine tumors, expanding its ...
US FDA expands use of Merck's cancer drug for adrenal gland tumors
The drug, Welireg, became the first FDA-approved oral treatment for the two tumors — pheochromocytoma and paraganglioma. The ...
Pharmaceutical Technology on MSN14h
GSK to spend $2bn on Phase III liver disease drug acquisition
Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...
Health1d
Ozempic Shows Promise in Treating a Severe Form of Liver Disease, Study Finds
A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...
The American Journal of Managed Care5d
Semaglutide Shows Promise for MASH Resolution, Severe Fibrosis: Naim Alkhouri, MD
Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...
Sagimet Biosciences Inc.: Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic ...
The Manila Times6d
Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
In January 2025, Sagimet delivered an oral presentation at the 9 th Annual MASH-TAG Conference highlighting the ...